Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
American Journal of Nephrology|February 7, 2017
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney DiseaseVicente E Torres, Olivier Devuyst, Arlene B Chapman, et al.
Journal of the American Society of Nephrology : JASN|December 7, 2016
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 TrialOlivier Devuyst, Arlene B Chapman, Ron T Gansevoort, et al.
Journal of Digital Imaging|May 28, 2017
Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic KidneysTimothy L Kline, Panagiotis Korfiatis, Marie E Edwards, et al.
Molecular and Cellular Biology|October 13, 2006
Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stressJaime D Blais, Christina L Addison, Robert Edge, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 26, 2016
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 TrialVicente E Torres, Eiji Higashihara, Olivier Devuyst, et al.
The New England Journal of Medicine|November 7, 2017
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney DiseaseVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 19, 2016
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled TrialNiek F Casteleijn, Jaime D Blais, Arlene B Chapman, et al.
Drug Safety|July 20, 2015
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials DatabasePaul B Watkins, James H Lewis, Neil Kaplowitz, et al.
Kidney International Reports|November 17, 2017
Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical TrialMaria V Irazabal, Jaime D Blais, Ronald D Perrone, et al.
Kidney International|March 23, 2019
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney diseaseRon T Gansevoort, Maatje D A van Gastel, Arlene B Chapman, et al.
Pageof 3